Study guide

5.1 Dental Pharmacology, Local Anesthetics, and Analgesics

Integrated National Board Dental Examination INBDE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: INBDE Exam Structure & Test Specifications

1.1 INBDE Format, Administration, Scoring & Retesting 1.2 The Domain of Dentistry: Test Specifications, Item Formats, Patient Boxes & Dental Charts

2 Chapter 2: Foundation Knowledge — Anatomic Sciences & Development

2.1 Gross & Head/Neck Anatomy and Histology 2.2 Oral Embryology, Tooth Development & Eruption 2.3 Genetic, Congenital & Developmental Conditions

3 Chapter 3: Foundation Knowledge — Biochemistry, Physiology & Physical Sciences

3.1 Biochemistry and Systemic Physiology 3.2 Physics & Chemistry of Oral Biology: pH, Diffusion & Demineralization

4 Chapter 4: Foundation Knowledge — Pathology, Microbiology & Immunology

4.1 General & Systemic Pathology 4.2 Microbiology, Immunology, and Infection Pathogenesis

5 Chapter 5: Foundation Knowledge — Pharmacology

5.1 Dental Pharmacology, Local Anesthetics, and Analgesics 5.2 Systemic Medications and Drug Interactions in Dentistry

6 Chapter 6: Foundation Knowledge — Dental Anatomy, Occlusion & Materials

6.1 Tooth Morphology, Anatomy, and Occlusion Biomechanics 6.2 Dental Materials Science, Biomaterials, and Impression Systems

7 Chapter 7: Patient Evaluation & Data Gathering

7.1 Chief Complaint, History Taking & Information from Diverse Sources 7.2 Comprehensive Patient History, Examination, and Medical Risk Assessment 7.3 Vital Signs, ASA Physical Status & Medical Risk Stratification 7.4 Normal Findings vs Significant Deviations Requiring Management

8 Chapter 8: Diagnostic Imaging

8.1 Dental Radiology Physics, Safety, and Imaging Interpretation 8.2 Intraoral Radiographic Technique, Errors & Quality Assurance 8.3 Radiographic Interpretation of Caries, Periapical & Bone Lesions 8.4 Panoramic, CBCT & Selection Criteria for Advanced Imaging

9 Chapter 9: Diagnostic Reasoning & Systemic Assessment

9.1 Diagnostic Testing, Laboratory Values, and Medical Complexities 9.2 Predictive Diagnostic Reasoning & Selecting the Right Diagnostic Test 9.3 Oral–Systemic Interrelationships 9.4 Differential Diagnosis of Orofacial Pain

10 Chapter 10: Oral Pathology & Mucosal Disease

10.1 Benign and Malignant Oral Pathology and Biopsy Protocols 10.2 Managing Oral Mucosal and Osseous Diseases

11 Chapter 11: Treatment Planning, Prognosis & Communication

11.1 Interdisciplinary Treatment Planning Sequencing and Prognosis 11.2 Prognosis Determination & Presenting Treatment Alternatives 11.3 Informed Consent, Refusal & Patient Education 11.4 Patient Attributes, Culture, Social Background & Care Across the Lifespan 11.5 Psychological, Social & Behavioral Principles in Patient Communication 11.6 Evaluating the Outcomes of Comprehensive Dental Care

12 Chapter 12: Medical & Dental Emergencies

12.1 Dental and Medical Emergencies in the Dental Office 12.2 Recognizing and Triaging Dental Emergencies

13 Chapter 13: Caries, Operative & Esthetic Dentistry

13.1 Caries Risk Assessment, Prevention, and Operative Dentistry 13.2 Adhesive Dentistry, Composite/Amalgam Restorations, and Esthetics 13.3 Managing the Esthetic Needs of Patients

14 Chapter 14: Endodontics

14.1 Pulpal Biology, Endodontic Diagnosis, and Emergency Treatment 14.2 Endodontic Therapy, Root Canal Instrumentation, Obturation, and Surgery

15 Chapter 15: Periodontics & Implantology

15.1 Periodontal Pathogenesis, Etiology, and Disease Classification 15.2 Non-Surgical Periodontal Therapy and Maintenance Protocols 15.3 Surgical Periodontics, Mucogingival Procedures, and Regenerative Care 15.4 Dental Implants: Planning, Surgical Placement, and Restorative Options

16 Chapter 16: Prosthodontics & Laboratory Communication

16.1 Fixed Prosthodontics: Crown/Bridge Preparation, Design, and Cementation 16.2 Removable Complete Dentures: Impression, Occlusion, and Delivery 16.3 Removable Partial Dentures: Components, Design, and Frameworks 16.4 Communicating Case Design to the Dental Laboratory

17 Chapter 17: Pain Control, Anesthesia & Oral Surgery

17.1 Local Anesthetic Techniques, Complications, and Nitrous Oxide Sedation 17.2 Dentoalveolar Surgery, Tooth Extraction, and Surgical Complications 17.3 Maxillofacial Trauma, Odontogenic Infections, and Complex Surgery

18 Chapter 18: Occlusion, TMD & Orthodontics

18.1 Craniofacial Growth, Development, and Orthodontic Diagnosis/Intervention 18.2 Developmental & Acquired Occlusal Problems 18.3 Temporomandibular Disorders: Diagnosis and Management

19 Chapter 19: Pediatric, Special Care & Vulnerable Patients

19.1 Pediatric Dental Care, Behavior Guidance, and Preventive Services 19.2 Pediatric Restorative Dentistry, Pulpal Therapy, and Dental Trauma 19.3 Special Care Dentistry: Geriatric, Special Needs, and Medically Compromised Patients 19.4 Recognizing, Managing & Reporting Patient Abuse and Neglect 19.5 Recognizing and Managing Substance Use Disorders

20 Chapter 20: Practice Management, Safety Systems & Informatics

20.1 Infection Control Protocols, Sterilization, and OSHA Compliance 20.2 Radiation Safety Guidelines, Dosimetry, and ALARA Principles 20.3 Practice Business Operations, OSHA & Regulatory Compliance 20.4 Catastrophe Preparedness & Practice Continuity Planning 20.5 Managing, Coordinating & Supervising Allied Dental Personnel 20.6 Quality Assurance, Assessment and Improvement 20.7 Dental Informatics, Electronic Records & Emerging Technology 20.8 Scope of Competence, Referral & Professional Self-Assessment

21 Chapter 21: Ethics, Jurisprudence, Evidence & Public Health

21.1 ADA Ethics Code, Jurisprudence, HIPAA, and Professional Conduct 21.2 Evidence-Based Dentistry, Clinical Epidemiology, and Dental Public Health 21.3 Biostatistics, Study Design & Critical Appraisal 21.4 Community Collaboration & Systems of Oral Health Care Delivery 21.5 Emerging Trends and Social/Economic Forces in Oral Health Care 21.6 Prevention, Intervention & Patient Education Strategies

5.1 Dental Pharmacology, Local Anesthetics, and Analgesics

Key Takeaways Explain This Topic AI

Local anesthetics block voltage-gated sodium channels from the intracellular membrane side, preventing nerve membrane depolarization and action potential conduction.

Amide local anesthetics are metabolized in the liver by cytochrome P450 enzymes (except articaine, which is 90% metabolized by plasma pseudocholinesterase), while ester local anesthetics are metabolized in plasma by pseudocholinesterase yielding PABA.

Lower pKa values closer to physiological pH (7.4) produce a higher fraction of un-ionized free base (RN), accelerating the onset of local anesthesia.

The maximum recommended epinephrine dose for cardiac-compromised patients is 0.04 mg (2 cartridges of 1:100,000 epi), compared to 0.2 mg (~11 cartridges) for healthy patients.

Maximum recommended doses for key local anesthetics are lidocaine 7 mg/kg with epinephrine (500 mg absolute max) and articaine 7 mg/kg (500 mg absolute max).

Last updated: August 2026

2.1 Dental Pharmacology, Local Anesthetics, and Analgesics

INBDE Core Concept: Local anesthetics prevent pain perception by reversibly blocking voltage-gated sodium channels from the intracellular side of the nerve membrane. Successful clinical administration requires a firm grasp of chemical structure, pKa-driven onset dynamics, tissue pH alterations, vasoconstrictor dosage limits, and precise calculation of maximum recommended doses (MRD).

Mechanism of Action & Sodium Channel Blockade

Local anesthetic (LA) molecules consist of three distinct structural components:

Lipophilic aromatic ring: Facilitates penetration through the lipid nerve sheath and cell membrane.

Intermediate chain: Determines chemical classification as an amide (ester linkage absent) or an ester (ester linkage present).

Hydrophilic secondary or tertiary amine: Acts as a proton acceptor, rendering the molecule soluble in aqueous solutions. Lipophilic Aromatic Group ── Intermediate Chain (Amide or Ester) ── Hydrophilic Amine

Intracellular Receptor Binding

Local anesthetics exist in solution in a dynamic equilibrium between two forms: the un-charged, un-ionized free base ( R N RN RN ) and the charged, ionized cation ( R N H + RNH^+ RN H + ). RNH + ⇌ RN + H + \text{RNH}^+ \rightleftharpoons \text{RN} + \text{H}^+ RNH + ⇌ RN + H +

Un-ionized Free Base ( R N RN RN ): Lipid-soluble form capable of diffusing across the hydrophobic nerve sheath (epineurium) and neuronal cell membrane.

Ionized Cation ( R N H + RNH^+ RN H + ): Water-soluble form that enters the open sodium channel pore from the intracellular side and binds to specific amino acid residues within the inner vestibule of the voltage-gated Na + \text{Na}^+ Na + channel .

By binding intracellularly, R N H + RNH^+ RN H + physically blocks the influx of sodium ions ( Na + \text{Na}^+ Na + ), preventing nerve membrane depolarization. As a result, the threshold potential is not reached, action potentials are not generated, and nociceptive impulses fail to propagate along the axon.

Chemical Structure: Amides vs. Esters

Understanding the distinction between amide and ester LAs is critical for predicting metabolism, elimination, and potential hypersensitivity reactions.

Classification Representative Drugs Primary Site of Metabolism Allergic Potential & Byproducts

Amides Lidocaine, Mepivacaine, Prilocaine, Bupivacaine, Articaine Hepatic (Cytochrome P450 enzymes) (Articaine is an exception) Extremely rare; true allergies are typically reactions to methylparaben preservatives in multi-dose vials.

Esters Procaine, Tetracaine, Benzocaine, Cocaine Plasma (Plasma pseudocholinesterase / butyrylcholinesterase) Higher; hydrolyzed into para-aminobenzoic acid (PABA) , a known potent allergen.

Memory Aid: Amide local anesthetics contain two "i"s in their generic name (L i doca i ne, Mep i vaca i ne, Art i ca i ne, Bup i vaca i ne, Pr i loca i ne). Ester LAs contain only one "i" (Proca i ne, Tetraca i ne, Benzoca i ne).

The Articaine Exception

Articaine is chemically unique: it contains a thiophene ring (which enhances lipid solubility) and an ester side chain in addition to its amide linkage. Because of this ester group, 90% of articaine is rapidly hydrolyzed in the blood by plasma pseudocholinesterase , leaving only 10% for hepatic metabolism. This rapid plasma clearance results in a significantly shorter elimination half-life (~27 minutes vs. ~90 minutes for lidocaine) and a lower systemic toxicity profile.

Pharmacokinetics: pKa, Tissue pH, and Onset of Action

The dissociation constant ( p K a pK_a p K a ​ ) of a local anesthetic represents the pH at which 50% of the drug exists in the un-ionized base form ( R N RN RN ) and 50% in the ionized cationic form ( R N H + RNH^+ RN H + ).

Lower p K a pK_a p K a ​ (closer to physiological pH 7.4): A higher percentage of un-ionized free base ( R N RN RN ) is available at physiological pH to penetrate the nerve membrane → \rightarrow → Faster onset of anesthesia .

Higher p K a pK_a p K a ​ : A smaller fraction of R N RN RN is available at pH 7.4 → \rightarrow → Slower onset of anesthesia .

  • Local Anesthetic p K a pK_a p K a ​ % R N RN RN at pH 7.4 Onset of Action
  • Mepivacaine 7.6 ~33% Fast (3–5 min)
  • Lidocaine 7.7 ~25% Fast (3–5 min)
  • Articaine 7.8 ~17% Fast (1–3 min, enhanced by thiophene ring)
  • Bupivacaine 8.1 ~15% Moderate/Slow (5–8 min)
  • Clinical Impact of Tissue Acidosis (Infection)

In inflamed or infected tissue, local anaerobic metabolism lowers extracellular pH from 7.4 to 5.5–6.0 . Applying the Henderson-Hasselbalch equation demonstrates that this acidic environment shifts the equilibrium heavily toward the ionized form ( R N H + RNH^+ RN H + ): pH − p K a = log ⁡ ( [ R N ] [ R N H + ] ) \text{pH} - pK_a = \log\left(\frac{[RN]}{[RNH^+]}\right) pH − p K a ​ = lo g ( [ RN H + ] [ RN ] ​ )

At pH 5.5, less than 1% of lidocaine exists as R N RN RN . Consequently, inadequate free base is available to cross the nerve membrane, explaining why local anesthetic injections frequently fail to produce adequate anesthesia in the presence of active tissue infection or abscesses .

Vasoconstrictors and Cardiac Dosage Limits

Vasoconstrictors (epinephrine, levonordefrin) are added to local anesthetics to counteract the intrinsic vasodilatory properties of LAs. Benefits include:

Decreased systemic absorption rate → \rightarrow → reduced systemic toxicity.

Increased depth and duration of anesthesia.

Localized hemostasis at the surgical site.

Epinephrine Pharmacology

Epinephrine acts on both α 1 \alpha_1 α 1 ​ receptors (causing localized vasoconstriction) and β 1 / β 2 \beta_1/\beta_2 β 1 ​ / β 2 ​ receptors (increasing heart rate, cardiac contractility, and bronchodilation).

Standard Dental Cartridge Volume: 1.8 mL (or 1.7 mL for articaine in some jurisdictions; calculations standardly use 1.8 mL).

Concentration Calculations:

1:100,000 epinephrine = 0.01 mg/mL × 1.8 mL = 0.018 mg epinephrine per cartridge 0.01\text{ mg/mL} \times 1.8\text{ mL} = \mathbf{0.018\text{ mg epinephrine per cartridge}} 0.01 mg/mL × 1.8 mL = 0.018 mg epinephrine per cartridge .

1:200,000 epinephrine = 0.005 mg/mL × 1.8 mL = 0.009 mg epinephrine per cartridge 0.005\text{ mg/mL} \times 1.8\text{ mL} = \mathbf{0.009\text{ mg epinephrine per cartridge}} 0.005 mg/mL × 1.8 mL = 0.009 mg epinephrine per cartridge .

1:50,000 epinephrine = 0.02 mg/mL × 1.8 mL = 0.036 mg epinephrine per cartridge 0.02\text{ mg/mL} \times 1.8\text{ mL} = \mathbf{0.036\text{ mg epinephrine per cartridge}} 0.02 mg/mL × 1.8 mL = 0.036 mg epinephrine per cartridge .

Maximum Recommended Epinephrine Doses Healthy Adult (Normal Max): 0.2 mg epi per appointment ( ≈ 11 cartridges of 1 : 100 , 000 ) Cardiac Risk / Medically Compromised: 0.04 mg epi per appointment ( ≈ 2.2 cartridges of 1 : 100 , 000 ) \begin{aligned}

\text{Healthy Adult (Normal Max):} & \quad \mathbf{0.2\text{ mg epi per appointment}} \quad (\approx 11 \text{ cartridges of } 1:100,000) \\

\text{Cardiac Risk / Medically Compromised:} & \quad \mathbf{0.04\text{ mg epi per appointment}} \quad (\approx 2.2 \text{ cartridges of } 1:100,000)

\end{aligned} Healthy Adult (Normal Max): Cardiac Risk / Medically Compromised: ​ 0.2 mg epi per appointment ( ≈ 11 cartridges of 1 : 100 , 000 ) 0.04 mg epi per appointment ( ≈ 2.2 cartridges of 1 : 100 , 000 ) ​

Clinical Scenario: A 62-year-old male with a history of myocardial infarction 8 months ago requires operative dentistry. To remain under the cardiac maximum epinephrine dose of 0.04 mg, the dentist can administer a maximum of 2 full cartridges of 2% lidocaine with 1:100,000 epinephrine.

Maximum Recommended Doses (MRD) Table & Calculations

Dosage limits must be calculated based on patient weight and absolute maximum caps. On the INBDE, dosages are routinely tested in milligrams per kilogram (mg/kg) or milligrams per pound (mg/lb).

  • Local Anesthetic Concentration mg per Cartridge Manufacturer MRD (mg/kg) Absolute Maximum Cap
  • Lidocaine 2% + 1:100k Epi 20 mg/mL 36 mg 7.0 mg/kg (3.2 mg/lb) 500 mg

Articaine 4% + 1:100k Epi 40 mg/mL 68 mg (articaine cartridges hold 1.7 mL , not 1.8 mL) 7.0 mg/kg (3.2 mg/lb) 500 mg

  • Mepivacaine 3% Plain 30 mg/mL 54 mg 6.6 mg/kg (3.0 mg/lb) 400 mg
  • Bupivacaine 0.5% + 1:200k Epi 5 mg/mL 9 mg 1.3 mg/kg (0.6 mg/lb) 90 mg
  • Prilocaine 4% Plain / 1:200k Epi 40 mg/mL 72 mg 8.0 mg/kg (3.6 mg/lb) 600 mg
  • Sample Dosage Calculation Problem

Patient: 20 kg pediatric patient requiring restorative treatment. Drug: 2% Lidocaine with 1:100,000 epinephrine.

Calculate Maximum Weight-Based Allowance: 20 kg × 7.0 mg/kg = 140 mg lidocaine 20\text{ kg} \times 7.0\text{ mg/kg} = \mathbf{140\text{ mg lidocaine}} 20 kg × 7.0 mg/kg = 140 mg lidocaine .

Determine mg per Cartridge: 2 % = 20 mg/mL × 1.8 mL = 36 mg/cartridge 2\% = 20\text{ mg/mL} \times 1.8\text{ mL} = \mathbf{36\text{ mg/cartridge}} 2% = 20 mg/mL × 1.8 mL = 36 mg/cartridge .

Calculate Maximum Cartridges: 140 mg / 36 mg/cartridge = 3.88 cartridges 140\text{ mg} / 36\text{ mg/cartridge} = \mathbf{3.88\text{ cartridges}} 140 mg /36 mg/cartridge = 3.88 cartridges (round down to 3.5 cartridges safely).

Toxicity Warning: Prilocaine and Benzocaine (topical) metabolize into o-toluidine , which oxidizes hemoglobin to methemoglobin. Methemoglobinemia manifests as cyanosis, slate-grey cutaneous discoloration, and hypoxia unresponsive to O 2 O_2 O 2 ​ . Antidote: Intravenous methylene blue (1–2 mg/kg).

Dental Analgesics & Prescribing Guidelines

Management of acute perioperative dental pain relies on non-opioid anti-inflammatory drugs as first-line therapy, reserving opioids for severe breakthrough pain.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Mechanism: Inhibit cyclooxygenase enzymes ( COX-1 and COX-2 ), blocking the conversion of arachidonic acid to pro-inflammatory prostaglandins.

First-Line Regimen: Ibuprofen 400–600 mg PO every 4 to 6 hours (ceiling analgesic effect achieved at 400 mg for mild-moderate pain).

Adverse Effects: Gastric mucosal ulceration (COX-1 inhibition), reversible platelet inhibition, nephrotoxicity, and blunting of antihypertensive medications.

Acetaminophen (APAP)

Mechanism: Acts predominantly in the central nervous system to inhibit prostaglandin synthesis; possesses analgesic and antipyretic properties but lacks peripheral anti-inflammatory or antiplatelet activity .

Maximum Daily Dose: 3,000 mg/day (standard healthy adult ceiling; 2,000 mg/day in chronic alcoholics or patients with hepatic impairment).

Toxicity: Overdose saturates glucuronide and sulfate conjugation pathways, converting APAP via CYP2E1 into N-acetyl-p-benzoquinone imine ( NAPQI ), a reactive metabolite causing hepatic necrosis. Antidote: N-acetylcysteine (NAC) , which replenishes hepatic glutathione stores.

Synergistic Multimodal Analgesia

Combining an NSAID with acetaminophen produces superior analgesia compared to opioid monotherapy without opioid-related side effects. Synergistic Post-Op Pain Protocol: Ibuprofen 400–600 mg + Acetaminophen 500–1000 mg Q6H \text{Synergistic Post-Op Pain Protocol:} \quad \text{Ibuprofen 400–600 mg} + \text{Acetaminophen 500–1000 mg Q6H} Synergistic Post-Op Pain Protocol: Ibuprofen 400–600 mg + Acetaminophen 500–1000 mg Q6H

Opioid Analgesics

Mechanism: μ \mu μ -opioid receptor agonists in the central nervous system (e.g., Codeine, Hydrocodone, Oxycodone, Tramadol).

Prescribing Guidelines: Limit initial prescriptions to a 3-day supply for acute dental pain. Common adverse effects include nausea, sedation, constipation, and respiratory depression.